Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Four leading healthcare academics in Oxford have received a prestigious national award.

© Shutterstock

The University of Oxford professors have been named National Institute of Health Research (NIHR) Senior Investigators in recognition of their “outstanding contribution to clinical and applied health and social care research”.

The successful candidates are all prominent researchers in the NIHR Oxford Biomedical Research Centre (BRC).

Together, the University of Oxford, Oxford Brookes University, Oxford University Hospitals NHS Foundation Trust and Oxford Health NHS Foundation Trust make up the Oxford Academic Health Science Centre (Oxford AHSC), a partnership that coordinates clinical and academic excellence across the partners.

Senior Investigators are appointed from NIHR Investigators through annual competitions, informed by the advice of an international panel of experts. In total, more than 300 Senior Investigators have now been appointed, with the number of active Senior Investigator awards maintained at around 200. They form part of the NIHR Faculty.

The new NIHR Senior Investigators are:

  • Professor Helen McShane, Director of the NIHR Oxford Biomedical Research Centre; Professor of Vaccinology, Nuffield Department of Medicine
  • Professor Ann Sarah Walker, Professor of Medical Statistics and Epidemiology, Nuffield Department of Medicine
  • Professor Matthew Costa, Professor of Orthopaedic Trauma, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences
  • Professor Richard McManus, Professor of Primary Care, Nuffield Department of Primary Care Health Sciences

As well as the new appointments, three professors who had previously held awards were designated Emeritus Senior Investigators.

Read more (NIHR Oxford BRC website)

Similar stories

PRINCIPLE Covid-19 treatments trial widens to under 50s and adds colchicine

Clinical Trials Coronavirus COVID-19 General Research

From today, the UK’s national priority platform trial of Covid-19 treatments for recovery at home launches its investigation of the gout drug colchicine, and expands for the first time to include adults of any age.

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

World’s largest clinical trial for COVID-19 treatments expands internationally

Clinical Trials Coronavirus COVID-19 General

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.